Completed PHASE4 INTERVENTIONAL 5-arm NCT03022435

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 4, 2012

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Influenza

Interventions High-Dose TIV LAIV TIV

Updated 9 times since 2017 Last updated: May 18, 2017 Started: Oct 31, 2012 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Influenza, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 9 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2017 — Jun 2018 [monthly]

Completed PHASE4
May 2017 — Jun 2017 [monthly]

Completed PHASE4
Feb 2017 — May 2017 [monthly]

Completed PHASE4

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.